Seed funding of $16M was raised by Surf Bio, a Palo Alto-based biopharmaceutical firm.
Breakout Ventures and Perceptive Xontogeny Venture Fund led the round.
The funds will be used by the company to develop an ultra-rapid insulin that can be used for the treatment of diabetes and improve its drug delivery platform using polymers.
Surf Bio, headed by Bryan Mazlish, is a preclinical biopharmaceutical firm that leverages a unique biotechnology platform to create enhanced therapeutic solutions in diabetes, oncology and gene therapy.
Surf Bio is a pioneer in ultra-rapid insulin and has established ongoing partnerships with numerous multinational pharmaceutical companies. To date, demonstrated in-vitro and in-vivo safety and efficacy data has generated significant interest from partners to evaluate the company’s technology within their proprietary product pipelines. The technology could be used to increase concentrations, reduce refrigeration dependence, and enable hard-to-formulate therapies.
Surf Bio Board of Directors is made up of the current founders Bryan Mazlish and Jennifer Schneider (MD), as well as new members Lindy Fishburne & Ben Askew (PhD).